RevieweLife2022
Integrating genomic and epidemiologic data to accelerate progress toward schistosomiasis elimination.
Review in eLife, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Population genomics reveals multi-scale mechanisms sustaining schistosomiasis re-emergence in a near-elimination setting.PLoS neglected tropical diseases · 2026Article
- Schistosoma Species and Hybrid Genotyping With a Field Deployable Multi-Marker Amplicon Panel.Current protocols · 2026Article
- Effects of Genetic polymorphism in susceptibility to schistosomiasis infection and adverse treatment outcomes.African health sciences · 2025Review
- Genetic analysis of Schistosoma mansoni in a low-transmission area in Brazil suggests population sharing between wild-hosts and humans and geographical isolation.PLoS neglected tropical diseases · 2025Article
- The research contribution of the Schistosomiasis Collection at the Natural History Museum (SCAN): highlights, challenges and future directions.Infectious diseases of poverty · 2025Review
- Priority knowledge gaps for schistosomiasis research and development in the World Health Organization Africa Region.Infectious diseases of poverty · 2025Article
- Therapeutic Potential of Natural Products in the Treatment ofMolecules (Basel, Switzerland) · 2023Review
- Human Schistosomiasis Vaccines as Next Generation Control Tools.Tropical medicine and infectious disease · 2023Article
- Prospects for genomic surveillance for selection in schistosome parasites.Frontiers in epidemiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The global community has adopted ambitious goals to eliminate schistosomiasis as a public health problem, and new tools are needed to achieve them. Mass drug administration programs, for example, have reduced the burden of schistosomiasis, but the identification of hotspots of persistent and reemergent transmission threaten progress toward elimination and underscore the need to couple treatment with interventions that reduce transmission. Recent advances in DNA sequencing technologies make whole-genome sequencing a valuable and increasingly feasible option for population-based studies of complex parasites such as schistosomes. Here, we focus on leveraging genomic data to tailor interventions to distinct social and ecological circumstances. We consider two priority questions that can be addressed by integrating epidemiological, ecological, and genomic information: (1) how often do non-human host species contribute to human schistosome infection? and (2) what is the importance of locally acquired versus imported infections in driving transmission at different stages of elimination? These questions address processes that can undermine control programs, especially those that rely heavily on treatment with praziquantel. Until recently, these questions were difficult to answer with sufficient precision to inform public health decision-making. We review the literature related to these questions and discuss how whole-genome approaches can identify the geographic and taxonomic sources of infection, and how such information can inform context-specific efforts that advance schistosomiasis control efforts and minimize the risk of reemergence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.